A practical reference on lyophilized powder: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-15. Anything still debated is marked as such rather than presented as settled.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
== HFE mutations and iron overload in other animals == The black rhinoceros (Diceros bicornis) can develop iron overload. To determine whether the HFE gene of black rhinoceroses has undergone mutation as an adaptive mechanism to improve iron absorption from iron-poor diets, Beutler et al. sequenced the entire HFE coding region of four species of rhinoceros (two browsing and two grazing species). Although HFE was well conserved across the species, numerous nucleotide differences were found between rhinoceros and human or mouse, some of which changed deduced amino acids. Only one allele, p.S88T in the black rhinoceros, was a candidate that might adversely affect HFE function. p.S88T occurs in a highly conserved region involved in the interaction of HFE and TfR1.
=== Administrative history === The ancient parish of Holyhead covered the majority of Holy Island. In 1832 a parliamentary borough was established covering just the area around the town itself, as a contributory borough to the Beaumaris Boroughs constituency. In 1860 a local government district was created covering the same area as the parliamentary borough, governed by an elected local board. Such local government districts were reconstituted as urban districts under the Local Government Act 1894. As part of the 1894 reforms, parishes were no long allowed to straddle district boundaries, and so the part of Holyhead parish outside the urban district became a separate parish called 'Holyhead Rural'. Holyhead Town Hall was completed in 1875 and served as both a public events venue and meeting place for the local board and the urban district council which replaced it. Holyhead Urban District was abolished in 1974, with its area instead becoming a community. District-level functions passed to Ynys Môn-Isle of Anglesey Borough Council, which in 1996 was reconstituted as a county council. The Holyhead Rural parish also became a community in 1974, and was renamed Trearddur in 1984.
=== Photodetector === A graphene/n-type silicon heterojunction has been demonstrated to exhibit strong rectifying behavior and high photoresponsivity. By introducing a thin interfacial oxide layer, the dark current of graphene/n-Si heterojunction has been reduced by two orders of magnitude at zero bias. At room temperature, the graphene/n-Si photodetector with interfacial oxide exhibits a specific detectivity up to 5.77 × 1013 cm Hz1/2 W2 at the peak wavelength of 890 nm in vacuum. In addition, the improved graphene/n-Si heterojunction photodetectors possess high responsivity of 0.73 A W−1 and high photo-to-dark current ratio of ≈107. These results demonstrate that graphene/Si heterojunction with interfacial oxide is promising for the development of high detectivity photodetectors. Recently, a graphene/si Schottky photodetector with record-fast response speed (< 25 ns) from wavelength 350 nm to 1100 nm are presented. The photodetectors exhibit excellent long-term stability even stored in air for more than 2 years. These results not only advance the development of high-performance photodetectors based on the graphene/Si Schottky junction, but also have important implications for mass-production of graphene-based photodetector array devices for cost-effective environmental monitoring, medical images, free-space communications, photoelectric smart-tracking, and integration with CMOS circuits for emerging interest-of-things applications, etc.
== External links == "Peptide P518 Receptor". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Sources: en.wikipedia.org
Constant hunger Unexplained weight loss Weight gain Flu-like symptoms, including weakness and fatigue Blurred vision Slow healing of cuts or bruises Tingling or loss of feeling in hands or feet Recurring gum or skin infections Recurring vaginal or bladder infections Acetone odor during diabetic ketoacidosis (DKA)
Flunisolide Fluticasone furoate Fluticasone propionate Triamcinolone acetonide Beclomethasone dipropionate Budesonide Mometasone furoate Ciclesonide There also exist certain combination preparations such as Advair Diskus in the United States, containing fluticasone propionate and salmeterol (a long-acting bronchodilator), and Symbicort, containing budesonide and formoterol fumarate dihydrate (another long-acting bronchodilator). They are both approved for use in children over 12 years old.
=== Hypersensitivity reaction === Lichenoid reaction: Intra-oral lesion which shares the appearance of lichen planus but arises due to contact hypersensitivity to certain dental materials or drug-induced.
Sources: en.wikipedia.org
=== Pregnancy === Paracetamol has long been established as a safe medication to treat short-term fever and significant pain in pregnant patients. Regulatory agencies, including the European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory Agency (MHRA), the World Health Organization (WHO), and the U.S. Food and Drug Administration (FDA) recommend paracetamol as a first-line analgesic and antipyretic in pregnancy, with use limited to situations where necessary, at the lowest effective dose, and for the shortest duration. Some observational studies have suggested a possible association between prenatal paracetamol use and neurodevelopmental disorders, including ADHD and autism. However, these studies are limited by confounding factors such as maternal fever and infection, and do not demonstrate causation. Large, well-controlled studies, including sibling-controlled analyses, find no causal link after adjusting for maternal conditions. In support of existing recommendations for its safe use during pregnancy, a 2026 review found that there were no clinically significant increases in the occurrence of autism, attention deficit hyperactivity disorder, or intellectual disability in the children of pregnant women who used paracetamol as directed. Untreated pain and fever can harm mother and fetus.
In February 2002, the Senate Select Committee on Intelligence and the House Permanent Select Committee on Intelligence formed a joint inquiry into the performance of the U.S. Intelligence Community. Their 832-page report released in December 2002 detailed failings of the FBI and CIA to use available information, including about terrorists the CIA knew were in the United States, to disrupt the plots. The joint inquiry developed its information about possible involvement of Saudi Arabian government officials from non-classified sources. The Bush administration demanded 28 related pages remain classified. In December 2002, the inquiry's chair Bob Graham revealed in an interview that there was "evidence that there were foreign governments involved in facilitating the activities of at least some of the terrorists in the United States." Victim families were frustrated by the unanswered questions and redacted material from the congressional inquiry and demanded an independent commission. September 11 victim families, members of Congress and the Saudi Arabian government are still seeking the release of the documents. In June 2016, CIA chief John Brennan said that he believes 28 redacted pages of a congressional inquiry into 9/11 will soon be made public, and that they will prove that the government of Saudi Arabia had no involvement in the September 11 attacks. In September 2016, Congress passed the Justice Against Sponsors of Terrorism Act that would allow relatives of victims of the September 11 attacks to sue Saudi Arabia for its government's alleged role in the attacks.
Chemical measures of water quality include dissolved oxygen (DO), chemical oxygen demand (COD), biochemical oxygen demand (BOD), total dissolved solids (TDS), pH, nutrients (nitrates and phosphorus), heavy metals, soil chemicals (including copper, zinc, cadmium, lead and mercury), and pesticides.
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.